Cempra, a pharmaceutical company focused on the treatment of infectious bacterial diseases, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering. The firm recently completed a Phase 2 clinical trial of its oral formulation CEM-101, which is designed to treat community acquired bacterial pneumonia (CABP). The Chapel Hill, NC-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol CEMP. Stifel Nicolaus Weisel, Leerink Swann, and Cowen & Company are the lead underwriters on the deal. No pricing terms were disclosed.
